[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-cancer":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,57,82,108,145,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100634739","enhanced-copd-management-in-suspected-lung-cancer-patients-100634739",false,"NCT07543601","Enhanced COPD Management in Suspected Lung Cancer Patients","Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention","ECHELON","Inclusion Criteria:\n\n* Undergoing diagnostic evaluation for suspected lung cancer\n* Spirometry showing obstructive airflow limitation (FEV₁\u002FFVC \\\u003C 75 % or FEV₁ \\\u003C 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation\n\nExclusion Criteria:\n\n* Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"NA","Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.\n\nThis study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.\n\nThe findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.",[27,28,29,30,31,32,33,34,35,36,37,38],"COPD (Chronic Obstructive Pulmonary Disease)","Lung Cancer (Diagnosis)","Lung Neoplasm Malignant","Lung Carcinoma","Pulmonary Neoplasms","Pulmonary Neoplasm","Pulmonary Cancers","Pulmonary Cancer","Pulmonary Carcinoma","COPD","COPD - Chronic Obstructive Pulmonary Disease","Airflow Obstruction, Chronic",[40,41,42,43],"Invesigation","Evaluation","Diagnostic Work-up","Diagnostic Pathway","RECRUITING","2026-04-15",{"date":47,"type":48},"2026-04-22","ACTUAL",{"date":50,"type":48},"2026-03-06",{"date":52,"type":21},"2027-06-30",{"name":54,"class":55},"Ditte Krag-Hansen","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":56},"100514385","contribution-of-the-cest-sequence-in-the-characterization-of-radionecrosis-of-brain-metastases-of-pulmonary-origin-100514385","NCT05977803","Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin","ACROP","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Histologically proven primary lung cancer\n* Histologically proven or not brain metastases\n* Irradiated metastases\n* Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy\n* Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI\n* Patients affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Opposition to the study\n* Contraindication to MRI\n* Refusal of imaging by the patient\n* Patient with state medical aid (unless exemption from affiliation)\n* Severe cognitive impairment making informed consent impossible\n* Patients under guardianship or deprived of liberty",{"count":65,"type":21},60,[24],"The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.",[69,70,34],"Brain Metastases","Radionecrosis",[72],"radionecrosis, metastases,","2026-03-26",{"date":75,"type":48},"2026-03-31",{"date":77,"type":48},"2024-02-15",{"date":79,"type":21},"2029-03-15",{"name":81,"class":55},"Assistance Publique - Hôpitaux de Paris",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":56},"100479346","phase-4-erector-spinae-block-for-thoracic-surgery-100479346","NCT05521789","Erector Spinae Block for Thoracic Surgery","Erector Spinae Blocks for Thoracic Surgery","Inclusion Criteria:\n\n* pulmonary resection\n* 18\\\u003Cage\\\u003C90\n\nExclusion Criteria:\n\n* pleurodesis\n* decortication\n* emergent surgery\n* local anesthetic allergy\n* intraoperative complication (inadvertent hemorrhage or conversion to open surgery)\n* bilateral pulmonary resection","90 Years",{"count":91,"type":21},70,[93],"PHASE4","The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.",[32,34,96,97,98],"Thoracic Diseases","Thoracic Cancer","Thoracic Neoplasms","2026-02-23",{"date":101,"type":48},"2026-02-25",{"date":103,"type":48},"2022-07-22",{"date":105,"type":21},"2027-07-21",{"name":107,"class":55},"George Washington University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":132,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":56},"100505180","precision-lung-cancer-survivorship-care-intervention-100505180","NCT05857995","Precision Lung Cancer Survivorship Care Intervention","Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities","KYLEADSII","Inclusion Criteria:\n\n* Have been diagnosed with lung cancer\n* Reside in a rural county as determined by a Rural Urban Continuum Code (RUC) of 4 or higher\n* Be at least 18 years of age or older\n* Be able to communicate effectively in English\n\nExclusion Criteria:\n\n* Have significant psychiatric disturbance that requires a higher level of care\n* Have substance abuse\u002Fdependence that requires a higher level of care\n* Are participating in another lung cancer survivorship care intervention\n* Have previously participated in the Kentucky LEADS Lung Cancer Survivorship Care Program",{"count":117,"type":21},300,[24],"The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.",[121,32,122,123,124,125,126,34,127,128,33,129,130,31,131],"Lung Cancer","Neoplasms, Lung","Neoplasms, Pulmonary","Neoplasm, Pulmonary","Cancer, Lung","Cancers, Lung","Cancer, Pulmonary","Cancers, Pulmonary","Cancer of the Lung","Cancer of Lung","Lung Cancers",[133,134,135,136],"Survivorship","Quality of Life","Behavioral Oncology","Psychosocial Oncology","2026-02-19",{"date":99,"type":48},{"date":140,"type":48},"2024-08-16",{"date":142,"type":21},"2028-03-31",{"name":144,"class":55},"Jerod L Stapleton, PhD",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":153,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":158,"conditions":159,"keywords":166,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":56},"100611099","early-phase-1-b-glucancer2--a-pilot-study-evaluating-a-new-method-for-cancer-detection-by-measuring-the-activity-of-different-glycosidase-enzymes-in-the-plasma-of-patients-with-a-localized-cancer-100611099","NCT07236177","B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.","Evaluation of a New Method for Detecting Cancer Pathologies by Measuring the Activity of Different Glycosidases in Plasma in Patients With Localized Cancer - Pilot Study: B-GLUCANCER2","B-GLUCANCER2","Inclusion Criteria:\n\n* Group 1: 40 patients with definitively diagnosed, untreated, localized solid breast cancer referred for initial surgical treatment.\n\nGroup 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment.\n\nGroup 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment.\n\nGroup 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer.\n\nExclusion Criteria:\n\n* Refusal to participate in the research.\n* Patients benefiting from enhanced protection, namely: minors, pregnant\u002Fbreastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a social care facility, adults under legal protection\n\nSpecific criteria for groups 1, 2, and 3:\n\n* Cancer patients undergoing oncological treatment.\n* Cancer not proven by anatomopathological examination.",true,{"count":155,"type":21},220,[157],"EARLY_PHASE1","The goal of this clinical trial is to develop a new cancer diagnostic and prognostic tool based on the dynamic and non-invasive detection of an exogenous volatile molecule, i.e., ethanol, from patients' samples.\n\nPatients' blood plasma will be analyzed with a mixture of volatile organic compound-based probes, each targeting a specific glycosidase. The presence of a given glycosidase in a blood sample would thus be revealed by the detection of an ethanol isotope in the gas phase.\n\n3 groups of patients with localized cancer (breast, prostate, pancreas) will be enrolled, as well as 1 group of patient without any cancer (control group).\n\nFor the patients, two 5ml plasma samples will be collected, one before and one after surgery for localized cancers. For healthy volunteers, only one 5ml plasma sample will be collected.\n\nThe primary objective will be to compare the levels of glycosidases measured in the blood of patients followed for localized cancer and referred for first surgery compared to control patients without cancer.",[160,161,34,162,163,164,165],"Breast Cancer","Pancreatic Cancer","Volatile Organic Compound","Glycosidase Activity","Probes","Tumor Markers, Biological",[167,168,169,170,171,172],"breast cancer","pancreatic cancer","pulmonary cancer","volatile organic compounds","glycosidase activity","localized cancer","2026-02-04",{"date":175,"type":48},"2026-02-05",{"date":177,"type":48},"2026-02-03",{"date":179,"type":21},"2028-03-03",{"name":181,"class":55},"Poitiers University Hospital",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100587908","tunisian-lung-cancer-study-100587908","NCT06934499","Tunisian Lung Cancer Study","Clinical Observational Study on Tunisian Lung Cancer","LUNG-TUN","Inclusion Criteria:\n\n* Age more than 18 years\n* Patients receiving health care in the departments of pulmonology, oncology, radiation oncology and thoracic surgery, whose diagnosis is confirmed histologically and\u002For by cytology, at least 3 months before the inclusion date\n* Informed consent\n\nExclusion Criteria:\n\n* None",{"count":191,"type":21},1334,"12 Months","OBSERVATIONAL","This is a prospective, multicenter, observational, national study. Eligible patients will be recruited consecutively among subjects with proven lung cancer, including any disease stage withclinical, therapeutic and evolutive discription.",[34],[34,197,198],"Registry","Tunisia","2025-06-02",{"date":201,"type":48},"2025-06-04",{"date":203,"type":48},"2025-05-02",{"date":205,"type":21},"2026-10-30",{"name":207,"class":55},"Dacima Consulting",2]